NEWS

Dr Mukesh Hariawala to receive India’s Most Admired Surgeon 2012 award

Wednesday, August 1, 2012

Mumbai: US-based artificial heart surgeon Dr Mukesh Hariawala will receive India’s Most Admired Surgeon 2012 award at the 5th Annual Pharmaceutical Leadership Summit and Business Leadership Awards 2012 in Mumbai on September 21.

Dr Mukesh Hariawala

The event will be organised by healthcare bi-monthly magazine Pharma Leaders, in association with the union ministry of commerce and industries and the Pharmaceuticals Export Promotion Council of India (Pharmexcil).

Dr Hariawala has done pioneering research work in the field of cardiac angiogenesis, which is the spontaneous development of new blood vessels in the heart by laser stimulation and subsequent injection of patients own stem cells harvested from bone marrow.

“The medical world often finds itself clueless when it comes to providing treatment to the patients with terminal heart disease who are not candidates for routine angioplasty, stent or bypass surgery. Such patients can benefit only by transplantation, which is not a practical solution due to severe shortage of donor hearts. However, Titanium VAD (Ventricular Assist Devices), which functions as an ‘Artificial Heart’, can give them a new life,” said Dr Hariawala.

Categories: NEWS

Tags: , , ,

  More from NEWS

Healthcare should be a mission with ethical & moral values: Rajnath Singh


Biosense Technologies raises $1 million in funding


World No Tobacco Day celebrated at ESIC Medical College


Pune doctors perform India’s first uterus transplant surgery


ICMR to test efficacy of two medicines for tackling drug-resistant TB


PGI Chandigarh to have two deans, one for academics and another for research

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.